Magnesium

For most people pursuing general repletion, sleep, and stress support, magnesium glycinate (also called bisglycinate) is the best default: high bioavailability, minimal GI effect, pleasant tolerability even at higher doses, and bundled with the calming amino acid glycine. If cognitive enhancement is the goal, magnesium L-threonate (Magtein) is the only form with clinical trial evidence for brain-penetrant effects (Liu et al., PMID 25589719), typically used alongside glycinate to achieve full-body repletion. For constipation relief, magnesium citrate is more effective due to its mild laxative effect. For cardiovascular indications, magnesium taurate combines two cardioprotective minerals. Avoid magnesium oxide except for the cheapest option—its bioavailability is poor and it produces diarrhea at lower doses than other forms. Most users do well with 200-400 mg elemental from glycinate at dinner or bedtime.

Standard serum magnesium tests (included in routine chemistry panels) measure only the <1% of total-body magnesium that circulates in blood—normal serum magnesium does not rule out cellular deficiency. A more sensitive test is red blood cell (RBC) magnesium, available at specialty labs. Symptoms suggesting deficiency include muscle cramps (especially nocturnal leg cramps), eyelid twitches, frequent tension headaches or migraines, poor sleep, high-perceived stress levels, constipation, palpitations or skipped beats, fatigue, and restless legs. Risk factors include low intake of dark leafy greens/nuts/whole grains, chronic alcohol use, long-term PPI use, loop or thiazide diuretic use, type 2 diabetes, inflammatory bowel disease, and age over 65. Given how common subclinical deficiency is (DiNicolantonio et al., PMID 29387438; Rosanoff et al., PMID 22365240), most adults can reasonably initiate supplementation at 200-300 mg elemental daily without testing, and observe for subjective response over 4-8 weeks.

Yes, with caveats about effect size and population. Abbasi et al. (PMID 23853635) randomized 46 older adults with insomnia to magnesium oxide 500 mg versus placebo for eight weeks and showed significant improvements in sleep efficiency, sleep latency, early-morning awakening, and biochemical markers (serum renin, melatonin, cortisol). An umbrella review (Arab et al., PMID 35989230) supports a modest effect particularly in older adults and those with baseline deficiency. Younger healthy adults without sleep complaints see smaller or negligible effects. Mechanism likely involves NMDA receptor voltage-gating (calming glutamatergic drive), GABA-A receptor enhancement, and parasympathetic modulation. Practical approach: magnesium glycinate 300-400 mg elemental at bedtime, often combined with glycine 3-5 g, expect improvement within 1-3 weeks if responsive.

Modestly, yes, particularly if you are deficient or hypertensive at baseline. Zhang et al. (PMID 27402922) pooled 34 randomized trials and found magnesium supplementation (median 368 mg/day for three months) produced approximately 2 mmHg systolic and 1.8 mmHg diastolic reductions. Effects are larger (3-5 mmHg) in hypertensive subgroups and smaller in normotensive populations. While a 2 mmHg change sounds small, at the population level it corresponds to meaningful reductions in stroke and coronary event rates. Magnesium is not a substitute for first-line antihypertensives in established hypertension but is a worthwhile adjunct and a reasonable lifestyle-tier intervention for borderline BP. Dose 300-500 mg elemental daily; pair with taurine 2-3 g daily, potassium-rich diet, weight control, and exercise for maximum effect.

Yes—magnesium has level B evidence ("probably effective") in American Academy of Neurology guidelines for migraine prevention. Peikert et al. (PMID 8792038) randomized 81 migraine patients to magnesium 600 mg/day (as trimagnesium dicitrate) versus placebo for 12 weeks; the magnesium group saw a 41.6% reduction in attack frequency compared to 15.8% on placebo. Facchinetti et al. (PMID 1860787) demonstrated similar benefits in menstrual migraine at 360 mg/day. Mauskop's 2018 review (PMID 29314056) summarizes the evidence. Mechanism involves correcting the magnesium deficiency common in migraineurs, NMDA receptor modulation, reduced cortical spreading depression, and reduced vasospasm. Typical prophylactic dose is 400-600 mg elemental daily, best split AM/PM to minimize GI effect. Full benefit usually emerges by weeks 8-12. Often combined with riboflavin 400 mg and CoQ10 100-200 mg for additive effect (see /compound/coq10).

For oral supplementation in adults with normal kidney function, toxicity is extremely unlikely because intestinal absorption is self-limiting and kidneys efficiently excrete excess. The dose-limiting effect is diarrhea, which is GI-tolerance not toxicity. The official upper limit (UL) from supplements is 350 mg elemental per day per National Academies, but this reflects the threshold where many people experience loose stool—it is not a toxicity threshold, and millions of people routinely exceed it safely with well-tolerated forms like glycinate. Real hypermagnesemia requires either chronic kidney disease (eGFR <30), massive acute ingestion of magnesium-containing laxatives, or intravenous administration. Symptoms of clinically significant excess include flushing, nausea, hyporeflexia, hypotension, and at extreme levels respiratory depression and cardiac arrest. If you have CKD, bradyarrhythmia, myasthenia gravis, or are taking digoxin, consult a clinician before supplementing. For healthy adults, 400-600 mg elemental daily from well-tolerated forms is safe indefinitely.

Not co-ingested at the exact same time, but functionally coupled in the biology. Magnesium is a cofactor for multiple enzymes in vitamin D metabolism including CYP27B1 (25-hydroxyvitamin D-1-alpha-hydroxylase, which converts 25(OH)D to active 1,25(OH)2D), CYP24A1, and vitamin D-binding protein synthesis (Uwitonze and Razzaque, PMID 29480918). Patients with concurrent magnesium deficiency respond poorly to vitamin D supplementation—serum 25(OH)D may rise but the downstream functional effects are blunted. Conversely, vitamin D modestly enhances intestinal magnesium absorption. Practical recommendation: anyone taking 1,000 IU or more of vitamin D daily should also be taking 200-400 mg elemental magnesium. Timing within the day is not critical; taking vitamin D at breakfast and magnesium glycinate at dinner/bedtime works well. See /compound/vitamin-d for detail on the reciprocal relationship and the broader vitamin D literature.

Possibly, for cognition specifically, but the evidence is narrower than marketing suggests. L-threonate is the only form demonstrated preclinically (Slutsky et al., PMID 20152124) to significantly raise brain magnesium concentrations in rodents and is the only form with human RCT data for cognition (Liu et al., PMID 25589719, 44 older adults with cognitive complaints showing improvements in executive function and working memory over 12 weeks at 1,500-2,000 mg compound daily). For the downstream cognitive question, it's plausibly superior. However: (1) total-body magnesium status matters for hundreds of other pathways and L-threonate supplies only ~144-200 mg elemental per standard dose, so cognitively-motivated users typically pair it with glycinate for full repletion; (2) some research groups question whether the brain-penetration advantage is as large in humans as in the original mouse model; (3) L-threonate is substantially more expensive than glycinate. Reasonable approach for cognition-focused users: L-threonate 1,500-2,000 mg split AM+PM plus glycinate 200-300 mg at bedtime.

Evidence is suggestive but not definitive. Tarleton et al. (PMID 28654669) conducted an open-label crossover trial of magnesium chloride 248 mg elemental daily in 126 adults with mild-to-moderate depression over six weeks, reporting clinically meaningful improvements in PHQ-9 scores that emerged within two weeks and disappeared within two weeks of stopping. The open-label design limits causal strength, but the rapid time course and effect size are mechanism-plausible. Observational studies link low dietary magnesium to higher depression incidence. Proposed mechanisms include NMDA receptor modulation (parallel to ketamine's pathway—see /compound/ketamine), GABA-A enhancement, and reduced HPA-axis reactivity. For anxiety, mechanistic evidence is stronger than clinical trial evidence, but users commonly report calmer baseline within 2-4 weeks of repletion. Practical role: magnesium is best viewed as foundational support and an adjunct to standard treatment (therapy, exercise, evidence-based medications), not a replacement. Dose: 300-500 mg elemental daily, glycinate form preferred.

Take it every day. Unlike some supplements where receptor downregulation argues for cycling, magnesium is a mineral that functions as an enzyme cofactor for over 600 reactions (Gröber et al., PMID 26404370)—there is no downregulation of need, only ongoing turnover as cells use ATP, synthesize glutathione, conduct nerve impulses, and so on. Skipping days simply returns cells to the deficient state. The body's magnesium economy favors steady intake: intestinal absorption is typically 30-50% of dose, higher at lower intakes, lower at higher intakes, so multiple smaller daily exposures capture more than infrequent large ones. Practical recommendation: one or two daily doses at consistent times (e.g., glycinate 200 mg dinner + 200 mg bedtime), taken every day indefinitely. If you travel or forget doses, simply resume without attempting to 'catch up'—the body will rebalance over days to weeks. The only reason to ever stop magnesium supplementation would be development of CKD, myasthenia gravis, or other specific contraindications as discussed elsewhere in this monograph.